<DOC>
	<DOC>NCT00155233</DOC>
	<brief_summary>1. Nalbuphine is opioid mu receptor antagonist and kappa receptor agonist 2. This study was designed to investigate the interaction between nalbuphine and morphine</brief_summary>
	<brief_title>Interaction Between Nalbuphine and Morphine in PCA</brief_title>
	<detailed_description>1. Nalbuphine is opioid mu receptor antagonist and kappa receptor agonist 2. This study was designed to investigate the interaction between nalbuphine and morphine 3. The analgesic effect and opioid-related side effects will be investigated</detailed_description>
	<mesh_term>Pain, Postoperative</mesh_term>
	<mesh_term>Morphine</mesh_term>
	<mesh_term>Nalbuphine</mesh_term>
	<criteria>1. Age 1865 y/o 2. Female patients of ASA physical status I to III 3. Scheduled for elective abdominal hysterectomy, myomectomy, or excision of ovarian tumor 1. Patients with a definite diagnosis of chronic pain syndrome, psychiatric disorders, or drug abuse (include opioids, NSAIDs, sedatives, antidepressants) 2. Intraoperative fentanyl use &gt; 3 Î¼g/kg 3. Patients with definite diagnosis of esophageal reflux syndrome 4. Use of sedatives, antiemetics, or antipruritics within 24 hours before operation 5. Surgery &gt; 4 hours or laparoscopy surgery</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2005</verification_date>
	<keyword>analgeisa</keyword>
	<keyword>postoperatve</keyword>
	<keyword>side effects</keyword>
</DOC>